Clinical Significance of an Alloantibody against the Kell Blood Group Glycoprotein | Zendy

Stella Maris Mattaloni | Zendy; Carine Prisco Ari | Zendy; Rosario Céspedes | Zendy; Claudia aka | Zendy; Carolina Trucco Boggione | Zendy; Melina Eliana Luján Brajovich | Zendy; Andrea Trejo | Zendy; Néstor Zani | Zendy; Claudia Biondi | Zendy; Lilian Castilho | Zendy; Carlos Miquel Cotorruelo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical Significance of an Alloantibody against the Kell Blood Group Glycoprotein

Author(s) -

Stella Maris Mattaloni,

Carine Prisco Ari,

Rosario Céspedes,

Claudia aka,

Carolina Trucco Boggione,

Melina Eliana Luján Brajovich,

Andrea Trejo,

Néstor Zani,

Claudia Biondi,

Lilian Castilho,

Carlos Miquel Cotorruelo

Publication year - 2016

Publication title -

transfusion medicine and hemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.971

H-Index - 39

eISSN - 1660-3818

pISSN - 1660-3796

DOI - 10.1159/000448381

Subject(s) - medicine , isoantibodies , blood group antigens , clinical significance , glycoprotein , immunology , antibody , biology , microbiology and biotechnology

Kell null (K 0 ) individuals can produce anti-Ku, an antibody against many epitopes in the Kell glycoprotein, after transfusion and/or pregnancy. Since sensitized K 0 patients are rare, little is known about anti-Ku clinical relevance and in particular about its association to hemolytic disease of the fetus and newborn.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research